Computer-Aided Drug Discovery Market to Reach $7.5 Billion by 2030
The global computer-aided drug discovery market was valued at $2.9 billion in 2021 and is projected to reach $7.5 billion by 2030, growing at an 11.48% CAGR, according to Allied Market Research.
The global market for computer-aided drug discovery (CADD) was valued at approximately $2.9 billion in 2021. Allied Market Research projects this market will reach $7.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.48% from 2022 to 2030.
CADD is employed in drug development to identify and optimize potential therapeutic compounds. The methodologies use software to design and analyze chemical structures, aiming to enhance efficacy and minimize adverse effects. This approach is widely adopted by pharmaceutical firms and academic institutions to streamline the discovery process.
Growth drivers include increased research and development activities in pharmaceuticals and vaccines, coupled with advancements in computational power. The integration of artificial intelligence (AI) and machine learning (ML) into CADD is accelerating the identification and development of drug candidates, which is expected to shorten clinical trial timelines and reduce failure rates.
The market is segmented by type, including structure-based drug design (SBDD) and ligand-based drug design (LBDD). Key therapeutic areas include oncology and neurology, with end-users comprising pharmaceutical companies, biotechnology firms, and research laboratories. Prominent players in the market include Schrödinger, Inc. and Charles River Laboratories.